Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial
Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail patients, who are frequently not capable of receiving standard therapy...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
26 August 2020
|
| In: |
BMC cancer
Year: 2020, Volume: 20 |
| ISSN: | 1471-2407 |
| DOI: | 10.1186/s12885-020-07264-8 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s12885-020-07264-8
|
| Author Notes: | Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1738040763 | ||
| 003 | DE-627 | ||
| 005 | 20240723135109.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201106s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12885-020-07264-8 |2 doi | |
| 035 | |a (DE-627)1738040763 | ||
| 035 | |a (DE-599)KXP1738040763 | ||
| 035 | |a (OCoLC)1264387270 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bozorgmehr, Farastuk |d 1979- |e VerfasserIn |0 (DE-588)141921811 |0 (DE-627)632526734 |0 (DE-576)326848150 |4 aut | |
| 245 | 1 | 0 | |a Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy |b study protocol of the TRADE-hypo trial |c Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken |
| 264 | 1 | |c 26 August 2020 | |
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 06.11.2020 | ||
| 520 | |a Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail patients, who are frequently not capable of receiving standard therapy regimens. Despite comprising the majority of lung cancer patients, this group is underrepresented in clinical trials. This applies also to elderly and frail patients suffering from unresectable stage III NSCLC, who are unfit for chemotherapy, and, therefore, cannot receive the standard therapy comprising of radiochemotherapy and the recently approved subsequent durvalumab consolidation therapy. These patients often receive radiotherapy only, which raises the concern of undertreatment. The TRADE-hypo trial aims at optimizing treatment of this patient group by combining radiotherapy with concomitant durvalumab administration, thereby employing the immune-promoting effects of radiotherapy, and determining safety, feasibility, and efficacy of this treatment. | ||
| 700 | 1 | |a Chung, Inn |e VerfasserIn |0 (DE-588)1017963711 |0 (DE-627)679809740 |0 (DE-576)354707841 |4 aut | |
| 700 | 1 | |a Christopoulos, Petros |d 1977- |e VerfasserIn |0 (DE-588)138659702 |0 (DE-627)604886756 |0 (DE-576)308488067 |4 aut | |
| 700 | 1 | |a Krisam, Johannes |d 1986- |e VerfasserIn |0 (DE-588)1016031343 |0 (DE-627)705475034 |0 (DE-576)351438696 |4 aut | |
| 700 | 1 | |a Schneider, Marc |d 1982- |e VerfasserIn |0 (DE-588)140634401 |0 (DE-627)620239948 |0 (DE-576)319208095 |4 aut | |
| 700 | 1 | |a Brückner, Lena Marie |d 1982- |e VerfasserIn |0 (DE-588)1042077339 |0 (DE-627)768220041 |0 (DE-576)393701093 |4 aut | |
| 700 | 1 | |a Müller, Daniel Wilhelm |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, Michael |e VerfasserIn |0 (DE-588)1054438781 |0 (DE-627)79152213X |0 (DE-576)41027089X |4 aut | |
| 700 | 1 | |a Rieken, Stefan |d 1979- |e VerfasserIn |0 (DE-588)135553385 |0 (DE-627)567062570 |0 (DE-576)278641725 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC cancer |d London : BioMed Central, 2001 |g 20(2020) Artikel-Nummer 806, 9 Seiten |h Online-Ressource |w (DE-627)326643710 |w (DE-600)2041352-X |w (DE-576)107014645 |x 1471-2407 |7 nnas |a Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy study protocol of the TRADE-hypo trial |
| 773 | 1 | 8 | |g volume:20 |g year:2020 |g extent:10 |a Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy study protocol of the TRADE-hypo trial |
| 787 | 0 | 8 | |i Errata |a Bozorgmehr, Farastuk, 1979 - |t Correction |d 2023 |w (DE-627)1896084788 |
| 856 | 4 | 0 | |u https://doi.org/10.1186/s12885-020-07264-8 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201106 | ||
| 993 | |a Article | ||
| 994 | |a 2020 | ||
| 998 | |g 135553385 |a Rieken, Stefan |m 135553385:Rieken, Stefan |d 910000 |d 911400 |d 50000 |e 910000PR135553385 |e 911400PR135553385 |e 50000PR135553385 |k 0/910000/ |k 1/910000/911400/ |k 0/50000/ |p 9 |y j | ||
| 998 | |g 1054438781 |a Thomas, Michael |m 1054438781:Thomas, Michael |d 910000 |d 950000 |d 950900 |d 50000 |e 910000PT1054438781 |e 950000PT1054438781 |e 950900PT1054438781 |e 50000PT1054438781 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |k 0/50000/ |p 8 | ||
| 998 | |g 140634401 |a Schneider, Marc |m 140634401:Schneider, Marc |d 910000 |d 950000 |d 950900 |e 910000PS140634401 |e 950000PS140634401 |e 950900PS140634401 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 5 | ||
| 998 | |g 1016031343 |a Krisam, Johannes |m 1016031343:Krisam, Johannes |d 910000 |d 999701 |e 910000PK1016031343 |e 999701PK1016031343 |k 0/910000/ |k 1/910000/999701/ |p 4 | ||
| 998 | |g 138659702 |a Christopoulos, Petros |m 138659702:Christopoulos, Petros |d 50000 |d 910000 |d 950000 |d 950900 |e 50000PC138659702 |e 910000PC138659702 |e 950000PC138659702 |e 950900PC138659702 |k 0/50000/ |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 3 | ||
| 998 | |g 1017963711 |a Chung, Inn |m 1017963711:Chung, Inn |d 910000 |d 950000 |d 950900 |e 910000PC1017963711 |e 950000PC1017963711 |e 950900PC1017963711 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 2 | ||
| 998 | |g 141921811 |a Bozorgmehr, Farastuk |m 141921811:Bozorgmehr, Farastuk |d 910000 |d 950000 |d 950900 |e 910000PB141921811 |e 950000PB141921811 |e 950900PB141921811 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950900/ |p 1 |x j | ||
| 999 | |a KXP-PPN1738040763 |e 3793109135 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 06.11.2020"],"origin":[{"dateIssuedKey":"2020","dateIssuedDisp":"26 August 2020"}],"id":{"eki":["1738040763"],"doi":["10.1186/s12885-020-07264-8"]},"language":["eng"],"person":[{"family":"Bozorgmehr","roleDisplay":"VerfasserIn","given":"Farastuk","display":"Bozorgmehr, Farastuk","role":"aut"},{"given":"Inn","role":"aut","display":"Chung, Inn","roleDisplay":"VerfasserIn","family":"Chung"},{"given":"Petros","display":"Christopoulos, Petros","role":"aut","roleDisplay":"VerfasserIn","family":"Christopoulos"},{"family":"Krisam","roleDisplay":"VerfasserIn","given":"Johannes","display":"Krisam, Johannes","role":"aut"},{"family":"Schneider","roleDisplay":"VerfasserIn","given":"Marc","role":"aut","display":"Schneider, Marc"},{"roleDisplay":"VerfasserIn","family":"Brückner","role":"aut","display":"Brückner, Lena Marie","given":"Lena Marie"},{"role":"aut","display":"Müller, Daniel Wilhelm","given":"Daniel Wilhelm","family":"Müller","roleDisplay":"VerfasserIn"},{"role":"aut","display":"Thomas, Michael","given":"Michael","family":"Thomas","roleDisplay":"VerfasserIn"},{"roleDisplay":"VerfasserIn","family":"Rieken","given":"Stefan","role":"aut","display":"Rieken, Stefan"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1738040763","title":[{"title_sort":"Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy","title":"Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy","subtitle":"study protocol of the TRADE-hypo trial"}],"physDesc":[{"extent":"10 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"id":{"eki":["326643710"],"issn":["1471-2407"],"zdb":["2041352-X"]},"origin":[{"dateIssuedDisp":"2001-","dateIssuedKey":"2001","publisher":"BioMed Central ; Springer","publisherPlace":"London ; Berlin ; Heidelberg"}],"pubHistory":["1.2001 -"],"note":["Gesehen am 22.05.20"],"disp":"Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy study protocol of the TRADE-hypo trialBMC cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"recId":"326643710","part":{"year":"2020","extent":"10","text":"20(2020) Artikel-Nummer 806, 9 Seiten","volume":"20"},"title":[{"title_sort":"BMC cancer","title":"BMC cancer"}],"language":["eng"]}],"name":{"displayForm":["Farastuk Bozorgmehr, Inn Chung, Petros Christopoulos, Johannes Krisam, Marc A. Schneider, Lena Brückner, Daniel Wilhelm Mueller, Michael Thomas, Stefan Rieken"]}} | ||
| SRT | |a BOZORGMEHRTHORACICRA2620 | ||